1. Home
  2. OMDA vs CTNM Comparison

OMDA vs CTNM Comparison

Compare OMDA & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

OMDA

Omada Health Inc.

HOLD

Current Price

$13.12

Market Cap

711.1M

Sector

Health Care

ML Signal

HOLD

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$13.24

Market Cap

480.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
OMDA
CTNM
Founded
2011
2009
Country
United States
United States
Employees
868
N/A
Industry
Medical/Nursing Services
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
711.1M
480.5M
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
OMDA
CTNM
Price
$13.12
$13.24
Analyst Decision
Buy
Buy
Analyst Count
11
4
Target Price
$21.73
$19.00
AVG Volume (30 Days)
846.7K
281.8K
Earning Date
05-17-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.46
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$24.94
N/A
Revenue Next Year
$20.18
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.28
$3.35
52 Week High
$26.92
$16.33

Technical Indicators

Market Signals
Indicator
OMDA
CTNM
Relative Strength Index (RSI) 53.72 48.70
Support Level $10.28 $10.17
Resistance Level $16.93 $13.18
Average True Range (ATR) 0.77 0.80
MACD 0.02 0.04
Stochastic Oscillator 87.23 45.27

Price Performance

Historical Comparison
OMDA
CTNM

About OMDA Omada Health Inc.

Omada Health Inc empowers individuals to make lasting health changes through personalized, virtual care between doctor's visits. The integrated platform of the company supports members with cardiometabolic conditions like prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health needs. The company's specialized care tracks also assist members using GLP-1 medications. The Company delivers measurable health outcomes and value for employers, health plans, health systems, and pharmacy benefit managers.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: